Non Small Cell Lung Cancer (NSCLC) Clinical Trial
Official title:
Active Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) Using Fibroblasts Transfected With DNA From Autologous Tumor (Phase IB Study)
NCT number | NCT00793208 |
Other study ID # | 08-004 |
Secondary ID | |
Status | Terminated |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | December 2008 |
Est. completion date | November 2015 |
Verified date | April 2019 |
Source | University of Pittsburgh |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study of the vaccine will proceed in two stages after the method of Simon (102). In the first stage, 15 patients will be accrued and treated. If two or fewer objective immunologic responses occur, the study will be terminated. If 3 or more responses are observed, the study will proceed to the second stage, accruing an additional 22 patients. If the second stage is complete and a total of 9 or more immunologic responses are observed among the 37 patients treated, the treatment response rate for the vaccine will be considered high enough to warrant further study. Conversely, if the evaluation of the vaccine concludes at the first stage, or if 8 or fewer total immunologic responses occur after completing the second stage, the vaccine will not be considered for further study.
Status | Terminated |
Enrollment | 1 |
Est. completion date | November 2015 |
Est. primary completion date | September 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Written informed consent conforming to the institutional guidelines obtained from the patient. - A diagnosis of non-small cell lung cancer (NSCLC), subjects will undergo or have had surgical resection. - Age 18 or above. - Karnofsky performance status > 70 - Adequate hematologic function: - Absolute neutrophil count > 1,000/mm3 - Absolute lymphocyte count > 1,000/mm3 - Hemoglobin > 9 g/dL - Platelets > 100,000/mm3 - Liver function tests: - Bilirubin (total) < 1.7 mg/dL - Alkaline phosphatase < 252 u/L - SGOT < 108 u/L - Kidney profile: - Serum electrolytes - Sodium 136-146 mEq/L - Potassium 3.5-5.0 mEq/L - Bicarbonate 21-31 mEq/L - Chloride 98-107 mmol/L - Serum creatinine < 3 x ULN - BUN 8-26 mg/dL - At least a 12 week interval should have elapsed between vaccination and any prior radiation therapy, chemotherapy or any other treatment. Patients should have recovered from surgery and adjuvant treatment. Exclusion Criteria: Subjects will be EXCLUDED from participation in the study if any of the following apply: - One or more of the Inclusion Criteria are not met. - A significant history or current evidence of cardiac disease including, but not limited to: congestive heart failure, coronary artery disease, angina pectoris, uncontrolled hypertension, serious arrythmias or myocardial infarction within the previous six months. - Evidence of active infection requiring antibiotic therapy. - Active intracranial metastases. Patients with previously resected intracranial disease and/or previously irradiated intracranial metastases that have been stable for four weeks are eligible. - Pregnant or lactating women. Pregnant women are excluded from this study. Women of childbearing potential must have a negative pregnancy test. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued if the mother is treated on study. - Patients requiring systemic corticosteroids (unless patient has had NO STEROIDS IN THE PAST 4 WEEKS). - Autoimmune disease including, but not limited to, rheumatoid arthritis, systemic lupus erythematous, multiple sclerosis, or ankylosing spondylitis - Patient must not have post-obstructive pneumonia or other serious infection at the time of registration or other serious underlying medical condition that would impair the ability of the patient to receive protocol treatment. - Subject is not a candidate for complete resection of the carcinoma via pneumonectomy, lobectomy, bilobectomy, extended wedge resection or anatomic segmentectomy with or without sleeve resection as noted in the surgical plan.. - Prior resection of lung cancer is allowed, if at least five years have elapsed between previous resection and registration. - No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the patient has been disease-free for at least 5 years prior to registration. - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. |
Country | Name | City | State |
---|---|---|---|
United States | University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania |
United States | University of Pittsburgh Cancer Institute - Hillman Cancer Center | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Theresa Whiteside, PhD | Immune Cell Therapy Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and feasibility; patients will be observed for treatment-related toxicity during and after each immunization,and for 1 h after immunization in the event that an immediate-type hypersensitivity reaction occurs. | 2.5 years | ||
Secondary | To evaluate the ability of the DNA-based vaccine to induce immune responses to the autologous tumor (if available) and/or the vaccine. | 14 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01204099 -
Study of PX-866 and Docetaxel in Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04083599 -
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00148798 -
Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)
|
Phase 3 | |
Recruiting |
NCT06026410 -
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02988817 -
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01005797 -
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
|
Phase 1 | |
Recruiting |
NCT00637910 -
Tarceva Italian Lung Optimization tRial
|
Phase 3 | |
Active, not recruiting |
NCT03447678 -
Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.
|
Phase 2 | |
Completed |
NCT02456246 -
Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT
|
N/A | |
Completed |
NCT02014324 -
Single Scope Staging of Lung Cancer With Endosonography
|
N/A | |
Terminated |
NCT01741155 -
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT01594398 -
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01323062 -
Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects
|
Phase 1 | |
Active, not recruiting |
NCT04772989 -
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01702844 -
Single Arm on the Tolerability of Weekly Nab-paclitaxel
|
Phase 2 | |
Completed |
NCT00492206 -
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
|
Phase 2 | |
Completed |
NCT00820417 -
Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
|
Phase 1 | |
Completed |
NCT02639026 -
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
|
Phase 1 | |
Completed |
NCT01282437 -
Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC
|
Phase 3 | |
Active, not recruiting |
NCT04721015 -
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
|
Phase 1 |